| Quarter | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
| 33 | 54 | 96 | 198 | 179 | 195 | |
Growth YoY Revenue Growth YoY% | 435.1 | 264.1 | ||||
| 29 | 42 | 100 | 172 | 155 | 155 | |
| 5 | 11 | -4 | 26 | 24 | 40 | |
OPM OPM% | 14.2 | 21.4 | -3.7 | 13.2 | 13.2 | 20.6 |
| 1 | 1 | 3 | 3 | 4 | 4 | |
Interest Expense Interest ExpenseCr | 2 | 2 | 5 | 8 | 9 | 9 |
Depreciation DepreciationCr | 1 | 1 | 6 | 8 | 8 | 25 |
PBT PBTCr | 2 | 9 | -12 | 12 | 10 | 10 |
| 1 | 3 | -5 | -1 | 2 | -1 | |
| 1 | 6 | -7 | 13 | 8 | 11 | |
Growth YoY PAT Growth YoY% | 457.8 | 65.5 | ||||
NPM NPM% | 4.3 | 11.9 | -6.9 | 6.7 | 4.4 | 5.4 |
| 0.1 | 34.4 | -2.2 | 4.0 | 1.8 | 2.4 |
| Quarter | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
| 33 | 54 | 96 | 198 | 179 | 195 | |
Growth YoY Revenue Growth YoY% | 435.1 | 264.1 | ||||
| 29 | 42 | 100 | 172 | 155 | 155 | |
| 5 | 11 | -4 | 26 | 24 | 40 | |
OPM OPM% | 14.2 | 21.4 | -3.7 | 13.2 | 13.2 | 20.6 |
| 1 | 1 | 3 | 3 | 4 | 4 | |
Interest Expense Interest ExpenseCr | 2 | 2 | 5 | 8 | 9 | 9 |
Depreciation DepreciationCr | 1 | 1 | 6 | 8 | 8 | 25 |
PBT PBTCr | 2 | 9 | -12 | 12 | 10 | 10 |
| 1 | 3 | -5 | -1 | 2 | -1 | |
| 1 | 6 | -7 | 13 | 8 | 11 | |
Growth YoY PAT Growth YoY% | 457.8 | 65.5 | ||||
NPM NPM% | 4.3 | 11.9 | -6.9 | 6.7 | 4.4 | 5.4 |
| 0.1 | 34.4 | -2.2 | 4.0 | 1.8 | 2.4 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
Revenue RevenueCr | 97 | 154 | 163 | 381 | 668 |
Growth Revenue Growth% | 58.9 | 6.1 | 133.6 | ||
| 79 | 122 | 124 | 342 | 581 | |
| 18 | 32 | 39 | 39 | 86 | |
OPM OPM% | 18.2 | 20.6 | 24.1 | 10.2 | 12.9 |
| 0 | 1 | 1 | 9 | 13 | |
Interest Expense Interest ExpenseCr | 5 | 11 | 12 | 18 | 32 |
Depreciation DepreciationCr | 6 | 9 | 8 | 17 | 47 |
PBT PBTCr | 7 | 13 | 20 | 12 | 20 |
| 3 | 4 | 5 | -2 | -4 | |
PAT PATCr | 4 | 8 | 14 | 14 | 25 |
Growth PAT Growth% | 92.3 | 71.4 | -1.2 | ||
NPM NPM% | 4.5 | 5.5 | 8.8 | 3.7 | 3.7 |
| 6.2 | 10.5 | 5.4 | 4.4 | 6.0 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
Revenue RevenueCr | 97 | 154 | 163 | 381 | 668 |
Growth Revenue Growth% | 58.9 | 6.1 | 133.6 | ||
| 79 | 122 | 124 | 342 | 581 | |
| 18 | 32 | 39 | 39 | 86 | |
OPM OPM% | 18.2 | 20.6 | 24.1 | 10.2 | 12.9 |
| 0 | 1 | 1 | 9 | 13 | |
Interest Expense Interest ExpenseCr | 5 | 11 | 12 | 18 | 32 |
Depreciation DepreciationCr | 6 | 9 | 8 | 17 | 47 |
PBT PBTCr | 7 | 13 | 20 | 12 | 20 |
| 3 | 4 | 5 | -2 | -4 | |
PAT PATCr | 4 | 8 | 14 | 14 | 25 |
Growth PAT Growth% | 92.3 | 71.4 | -1.2 | ||
NPM NPM% | 4.5 | 5.5 | 8.8 | 3.7 | 3.7 |
| 6.2 | 10.5 | 5.4 | 4.4 | 6.0 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|
Equity Capital Equity CapitalCr | 7 | 13 | 13 | 22 | 312 |
Reserves ReservesCr | 24 | 61 | 80 | 469 | 184 |
| 77 | 153 | 162 | 573 | 464 | |
| 26 | 39 | 14 | 356 | 348 | |
| 134 | 268 | 272 | 1,424 | 1,320 | |
| 82 | 187 | 200 | 822 | 635 | |
| 52 | 81 | 72 | 602 | 685 | |
| 134 | 268 | 272 | 1,424 | 1,320 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|
Equity Capital Equity CapitalCr | 7 | 13 | 13 | 22 | 312 |
Reserves ReservesCr | 24 | 61 | 80 | 469 | 184 |
| 77 | 153 | 162 | 573 | 464 | |
| 26 | 39 | 14 | 356 | 348 | |
| 134 | 268 | 272 | 1,424 | 1,320 | |
| 82 | 187 | 200 | 822 | 635 | |
| 52 | 81 | 72 | 602 | 685 | |
| 134 | 268 | 272 | 1,424 | 1,320 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| -13 | -30 | 33 | 93 | |
| -19 | -46 | 0 | -274 | |
| 24 | 79 | -36 | 596 | |
Net Cash Flow Net Cash FlowCr | -8 | 2 | -2 | 415 |
Free Cash Flow Free Cash FlowCr | -29 | -65 | 42 | 75 |
CFO To PAT CFO To PAT% | -292.5 | -353.7 | 229.8 | 652.6 |
CFO To EBITDA CFO To EBITDA% | -72.6 | -94.0 | 84.2 | 240.4 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| -13 | -30 | 33 | 93 | |
| -19 | -46 | 0 | -274 | |
| 24 | 79 | -36 | 596 | |
Net Cash Flow Net Cash FlowCr | -8 | 2 | -2 | 415 |
Free Cash Flow Free Cash FlowCr | -29 | -65 | 42 | 75 |
CFO To PAT CFO To PAT% | -292.5 | -353.7 | 229.8 | 652.6 |
CFO To EBITDA CFO To EBITDA% | -72.6 | -94.0 | 84.2 | 240.4 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|---|
Market Cap Market CapitalizationCr | 2,175 | ||||
Price To Earnings Price To Earnings | 82.5 | ||||
Price To Sales Price To Sales | 3.3 | ||||
Price To Book Price To Book | 10.6 | ||||
EV To EBITDA EV To EBITDA | 28.0 | ||||
GPM GPM% | 37.0 | 35.3 | 39.3 | 34.8 | 34.8 |
OPM OPM% | 18.2 | 20.6 | 24.1 | 10.2 | 12.9 |
NPM NPM% | 4.5 | 5.5 | 8.8 | 3.7 | 3.7 |
ROCE ROCE% | 12.1 | 12.2 | 17.0 | 3.2 | 6.2 |
ROE ROE% | 13.9 | 11.3 | 15.4 | 2.9 | 5.0 |
ROA ROA% | 3.3 | 3.1 | 5.3 | 1.0 | 1.9 |
| Financial Year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|---|
Market Cap Market CapitalizationCr | 2,175 | ||||
Price To Earnings Price To Earnings | 82.5 | ||||
Price To Sales Price To Sales | 3.3 | ||||
Price To Book Price To Book | 10.6 | ||||
EV To EBITDA EV To EBITDA | 28.0 | ||||
GPM GPM% | 37.0 | 35.3 | 39.3 | 34.8 | 34.8 |
OPM OPM% | 18.2 | 20.6 | 24.1 | 10.2 | 12.9 |
NPM NPM% | 4.5 | 5.5 | 8.8 | 3.7 | 3.7 |
ROCE ROCE% | 12.1 | 12.2 | 17.0 | 3.2 | 6.2 |
ROE ROE% | 13.9 | 11.3 | 15.4 | 2.9 | 5.0 |
ROA ROA% | 3.3 | 3.1 | 5.3 | 1.0 | 1.9 |
| Market CapitalizationMkt CapCr | 4,194 | 2,901 | 2,757 | 2,175 | 2,143 | 1,841 | 1,593 |
| Close PriceClose₹ | 418.25 | 1,693.90 | 317.05 | 492.30 | 232.15 | 1,655.40 | 2,312.00 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 52.41 | 51.49 | 32.48 | 82.46 | 67.68 | 33.99 | |
| Price To SalesPS | 4.06 | 3.34 | 3.66 | 3.26 | 1.12 | 4.14 | 4.04 |
| RevenueRevenueCr | 1,032 | 870 | 753 | 668 | 1,909 | 444 | 395 |
| Revenue Growth TTMRev Gr TTM% | 18.2% | 30.1% | 10.6% | 15.2% | 10.6% | ||
| PAT Growth TTMPAT Gr TTM% | 40.7% | -64.3% | 127.6% | 27.3% | 64.3% |
| Market CapitalizationMkt CapCr | 4,194 | 2,901 | 2,757 | 2,175 | 2,143 | 1,841 | 1,593 |
| Close PriceClose₹ | 418.25 | 1,693.90 | 317.05 | 492.30 | 232.15 | 1,655.40 | 2,312.00 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 52.41 | 51.49 | 32.48 | 82.46 | 67.68 | 33.99 | |
| Price To SalesPS | 4.06 | 3.34 | 3.66 | 3.26 | 1.12 | 4.14 | 4.04 |
| RevenueRevenueCr | 1,032 | 870 | 753 | 668 | 1,909 | 444 | 395 |
| Revenue Growth TTMRev Gr TTM% | 18.2% | 30.1% | 10.6% | 15.2% | 10.6% | ||
| PAT Growth TTMPAT Gr TTM% | 40.7% | -64.3% | 127.6% | 27.3% | 64.3% |